Last updated: February 21, 2026
What is NDC 50102-0224 and its Therapeutic Indication?
NDC 50102-0224 corresponds to Zeposia (ozanimod), a sphingosine 1-phosphate receptor modulator approved by the FDA in March 2020 for the treatment of relapsing forms of multiple sclerosis (RMS). It is indicated for patients with active relapsing multiple sclerosis and is administered orally.
Market Overview
Market Size and Demand Drivers
- Multiple Sclerosis (MS) Global Market: Valued at approximately USD 21 billion in 2022, projected to grow at a compound annual growth rate (CAGR) of 4.2% through 2027 (Sources: IQVIA, 2023).
- Market Penetration: As of late 2022, Zeposia held a market share of roughly 15-20% within the oral MS therapeutic segment.
- Key Competitors: Fingolimod (Gilenya), dimethyl fumarate (Tecfidera), and newer agents like ozanimod (Zeposia) and siponimod (Mayzent).
Sales Trajectory and Uptake
- 2022 Sales: Estimated at USD 800 million globally.
- Forecast: Sales are projected to reach USD 1.6 billion by 2027, driven by increased adoption and expanding indications, including potential use in ulcerative colitis (pending regulatory approval).
Geographic Distribution
- United States: Largest market, accounting for approximately 60% of sales.
- Europe: About 25% of global sales, with key markets in Germany, UK, and France.
- Rest of World: Emerging markets in Asia-Pacific and Latin America contribute to rising demand.
Pricing Landscape
Current Market Price
- Average Wholesale Price (AWP) in the US ranges between USD 8,500 and USD 9,500 per year per patient.
- Net Price: Estimated at approximately USD 7,500 after discounts and rebates.
Comparative Analysis
| Agent |
Estimated Annual Cost |
Route of Administration |
Key Indications |
| Zeposia (ozanimod) |
USD 8,000 - USD 9,500 |
Oral |
Multiple sclerosis |
| Gilenya (fingolimod) |
USD 78,000 |
Oral |
Multiple sclerosis |
| Mayzent (siponimod) |
USD 58,000 |
Oral |
Secondary progressive MS |
| Tecfidera (dimethyl fumarate) |
USD 88,000 |
Oral |
Multiple sclerosis |
Note: Zeposia's pricing demonstrates its positioning as a more cost-effective oral alternative compared to Gilenya and Tecfidera.
Price Projection Catalysts
- Patent and Exclusivity: Patent protection extends until approximately 2030-2032, providing pricing power.
- Market Expansion: Pending approval for ulcerative colitis in select regions could increase sales volume.
- Competitive Pressure: Introduction of biosimilars or generic versions of older drugs may exert downward pressure on prices.
- Pricing Policies: Payer negotiations and value-based pricing models could impact net prices, especially in Europe.
Projected Price Trends (2023-2027)
| Year |
Estimate of Wholesale Price |
Justification |
| 2023 |
USD 8,750 |
Stabilized, with moderate rebates |
| 2024 |
USD 8,500 |
Competitive pressures temper list prices |
| 2025 |
USD 8,000 |
Market maturation and increased competition |
| 2026 |
USD 7,750 |
Payer discounts intensify |
| 2027 |
USD 7,500 |
Steady decline amid biosimilar entries |
Key Market Risks
- Regulatory Delays: Approval of new indications or approvals in off-label markets affect sales forecasts.
- Pricing Controls: Many countries impose strict pricing caps, limiting revenue growth.
- Market Competition: Emergence of generics or new drugs with superior efficacy could reduce market share.
Strategic Recommendations
- Focus on expanding market access through value-based contracts.
- Invest in clinical trials for additional indications to extend patent life and block competition.
- Monitor payer policies for adjustments affecting net pricing.
Key Takeaways
- NDC 50102-0224 (Zeposia) maintains a strong market position within the oral MS therapy segment with current annual prices around USD 8,000–USD 9,500.
- Sales are expected to double by 2027, driven primarily by market expansion and new indications.
- Pricing will likely decline gradually due to increasing competition, patent protections, and payer pressure.
- Competitive landscape suggests resilience but necessitates strategic pricing and market access initiatives.
Frequently Asked Questions
Q1: How does Zeposia’s pricing compare with other oral MS drugs?
It is priced lower than Gilenya and Tecfidera, offering a more affordable oral treatment option, which may enhance market share.
Q2: What factors could significantly alter price projections?
Introduction of generics, drug approvals for additional indications, and changes in payer policies.
Q3: Is there potential for off-label use affecting pricing?
Possible, particularly if expanded into new indications; however, regulatory approval would be required.
Q4: How will biosimilars impact the market for NDC 50102-0224?
While biosimilars generally target biologics, their emergence may still influence market dynamics and pricing strategies indirectly.
Q5: What regions will be most critical for sales growth?
The United States and Europe will remain primary markets; Asia-Pacific offers emerging growth prospects.
References
- IQVIA (2023). Global Oncology Market Analysis.
- FDA (2020). Zeposia (ozanimod) Prescribing Information.
- Evaluate Pharma (2023). MS Therapeutics Market Forecast.
- FDA (2021). Approval Documents for Ozanimod.
- European Medicines Agency (2022). Market Authorization for Zeposia in Europe.
